DEC 2020

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1312630

Contents of this Issue


Page 136 of 138

*In some patients with continued daily use. One drop in each eye, twice daily (approximately 12 hours apart). 3 † XiidraisanLFA-1antagonistforthetreatmentofdryeyedisease.Pivotaltrialdata:ThesafetyandefficacyofXiidrawereassessedinfour 12-week,randomized,multicenter,double-masked,vehicle-controlledstudies(N=2133).Patientsweredosedtwicedaily.Useofartificial tearswasnotallowedduringthestudies.Thestudyendpointsincludedassessmentofsigns(basedonInferiorfluoresceinCornealStaining Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100). 3 A larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at 2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials. Effects on signs of dry eye disease ICSS (on a scale from 0-4; 0=no staining; 4=coalescent) was recorded at each study visit. At day 84, a larger reduction in inferior corneal staining favoring Xiidra was observed in 3 of the 4 studies. 3 Indication Xiidra ® (lifitegrastophthalmicsolution)5%isindicatedforthetreatmentofsignsandsymptomsofdryeyedisease(DED). Important Safety Information • Xiidraiscontraindicatedinpatientswithknownhypersensitivitytolifitegrastortoanyoftheotheringredients. Not an actual patient. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080

Articles in this issue

Archives of this issue

view archives of Eyeworld - DEC 2020